KR900017580A - 표피 성장 인자를 함유하는 안정화된 조성물 - Google Patents

표피 성장 인자를 함유하는 안정화된 조성물 Download PDF

Info

Publication number
KR900017580A
KR900017580A KR1019900006828A KR900006828A KR900017580A KR 900017580 A KR900017580 A KR 900017580A KR 1019900006828 A KR1019900006828 A KR 1019900006828A KR 900006828 A KR900006828 A KR 900006828A KR 900017580 A KR900017580 A KR 900017580A
Authority
KR
South Korea
Prior art keywords
egf
composition
zinc
mixture
composition containing
Prior art date
Application number
KR1019900006828A
Other languages
English (en)
Inventor
케이. 시니 존
엘. 핀케나우어 에이미
Original Assignee
폴 콜레티
에티콘 인코포레이티드
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by 폴 콜레티, 에티콘 인코포레이티드 filed Critical 폴 콜레티
Publication of KR900017580A publication Critical patent/KR900017580A/ko

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/28—Compounds containing heavy metals
    • A61K31/315—Zinc compounds
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/02—Inorganic compounds
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • A61K38/17—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • A61K38/18—Growth factors; Growth regulators
    • A61K38/1808—Epidermal growth factor [EGF] urogastrone
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/06—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite
    • A61K47/08—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite containing oxygen, e.g. ethers, acetals, ketones, quinones, aldehydes, peroxides
    • A61K47/12—Carboxylic acids; Salts or anhydrides thereof
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/0012—Galenical forms characterised by the site of application
    • A61K9/0014—Skin, i.e. galenical aspects of topical compositions

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Epidemiology (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Health & Medical Sciences (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Engineering & Computer Science (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Zoology (AREA)
  • Inorganic Chemistry (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Immunology (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Oil, Petroleum & Natural Gas (AREA)
  • Dermatology (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Inorganic Compounds Of Heavy Metals (AREA)
  • Peptides Or Proteins (AREA)
  • Medicinal Preparation (AREA)

Abstract

내용 없음

Description

표피 성장 인자를 함유하는 안정화된 조성물
본 내용은 요부공개 건이므로 전문내용을 수록하지 않았음
제1도는 숙성된 EGF의 용액을 역상 HPLC로 분석한후 EGF피크 C, D, X 및 Y의 관계를 나타내는 크로마토그램이다.

Claims (14)

  1. 약제학적 유효량의 인체 표피 성장 인자(EGF) 및 EGF의 분해를 방지하기에 충분한 양의 아연 이온을 함유하는 약제학적 조성물.
  2. 아연과 EGF의 착물의 염을 함유하는 결정성 EGF 조성물.
  3. EGF와 아연 이온을 제형화시키는 단계를 특징으로 하는, 제1항의 조성물의 제조방법.
  4. EGF를 함유하는 약제학적 조성물 중으로 생물학적 활성의 상실에 대해 EGF를 안정화시키기에 충분한 양의 아연 이온을 혼입시킴을 특징으로 하여, EGF를 함유하는 약제학적 조성물을 안정화시키는 방법.
  5. 제1항에 있어서, 완충 수용액의 형태인 조성물.
  6. 제1항에 있어서, 겔의 형태인 조성물.
  7. 제1항에 있어서, 크림의 형태인 조성물.
  8. 제1항에 있어서, 중성 유전상수 환원 화합물을 추가로 함유하는 조성물.
  9. 제1항에 있어서, 약 4.0내지 약 7.0범위의 pH를 갖는 조성물
  10. 제9항에 있어서, pH가 약 5.5 내지 약6.0범위인 조성물.
  11. 제1항에 있어서, 250㎍ EGF/ml 당 약 10 내지 20mM의 아연 양이온을 갖는 조성물.
  12. 제5항에 있어서, 완충액이 아세테이트 완충액인 조성물.
  13. a)EGF의 수용액을 제조하고, b)수용액 또는 고체 형태로 아연을 상기 EGF용액을 가하여 250㎍ EGF/ml 당 약 10 내지 20mM의 아연이 사용되는, 아연과EGF의 혼합물을 생성시키고, c)혼합물의 pH를 4.0 내지 7.0의 범위로 조절하고, d)아연-EGF 결정을 생성시키고, e)결정성 아연-EGF를 혼합물로부터 회수함을 특징으로 하여, 결정성 인체 EGF를 제조하는 방법.
  14. EGF를 충분한 아연 이온과 배합하여 분해에 대해 EGF를 안정화시킴을 특징으로 하여, 안정화된 EGF 조성물을 제조하는 방법.
    ※ 참고사항 : 최초출원내용에 의하여 공개하는 것임.
KR1019900006828A 1989-05-16 1990-05-14 표피 성장 인자를 함유하는 안정화된 조성물 KR900017580A (ko)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US353131 1989-05-16
US07/353,131 US5130298A (en) 1989-05-16 1989-05-16 Stabilized compositions containing epidermal growth factor

Publications (1)

Publication Number Publication Date
KR900017580A true KR900017580A (ko) 1990-12-19

Family

ID=23387889

Family Applications (1)

Application Number Title Priority Date Filing Date
KR1019900006828A KR900017580A (ko) 1989-05-16 1990-05-14 표피 성장 인자를 함유하는 안정화된 조성물

Country Status (11)

Country Link
US (1) US5130298A (ko)
EP (1) EP0398619B1 (ko)
JP (1) JP2763815B2 (ko)
KR (1) KR900017580A (ko)
AU (1) AU630952B2 (ko)
CA (1) CA2016659C (ko)
DE (1) DE69002795T2 (ko)
DK (1) DK0398619T3 (ko)
ES (1) ES2058799T3 (ko)
GR (1) GR1000392B (ko)
PT (1) PT94037B (ko)

Families Citing this family (44)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US6326154B1 (en) * 1990-11-19 2001-12-04 Genentech, Inc. Ligand-mediated immunofunctional hormone binding protein assay method
AU2489992A (en) * 1991-08-16 1993-03-16 Chiron Corporation Muteins of epidermal growth factor exhibiting enhanced binding at low ph
US5618544A (en) * 1992-08-12 1997-04-08 Bays-Brown Dermatologics, Inc. Method of decreasing cutaneous senescence
US5759548A (en) * 1993-11-30 1998-06-02 Lxr Biotechnology Inc. Compositions which inhibit apoptosis, methods of purifying the compositions and uses thereof
WO1995022560A1 (en) * 1994-02-22 1995-08-24 The Syntex-Synergen Neuroscience Joint Venture Pharmaceutical formulations of cntf
US6048545A (en) * 1994-06-24 2000-04-11 Biozone Laboratories, Inc. Liposomal delivery by iontophoresis
CN1043732C (zh) * 1994-12-22 1999-06-23 大连医科大学 治疗口腔糜烂面的新型药膜
US5807315A (en) * 1995-11-13 1998-09-15 Minimed, Inc. Methods and devices for the delivery of monomeric proteins
US6593456B1 (en) * 1996-11-06 2003-07-15 The Regents Of The University Of California Tumor necrosis factor receptor releasing enzyme
US20050191661A1 (en) * 1996-11-06 2005-09-01 Tetsuya Gatanaga Treatment of inflammatory disease by cleaving TNF receptors
IL129787A0 (en) 1996-11-06 2000-02-29 Univ California Isolated tumor necrosis factor receptor releasing enzyme compositions comprising the enzyme and methods of the use thereof
US6495532B1 (en) * 1997-03-19 2002-12-17 Sky High, Llc Compositions containing lysophosphotidic acids which inhibit apoptosis and uses thereof
US6949528B1 (en) 1998-03-18 2005-09-27 Goddard John G Compositions containing lysophosphatidic acids which inhibit apoptosis and uses thereof
US7033615B2 (en) * 1999-07-09 2006-04-25 Cancer2 Inc. Methods for regulating levels of zinc, cadmium and calcium in humans and for diagnosing, or screening for the risk of developing, diseases associated with abnormal levels of cadmium, zinc and calcium in body fluids and tissues
US6541447B1 (en) 1999-09-01 2003-04-01 B & M Healthcare Technologies, Inc. Wound healing composition and method for use thereof
GB0001621D0 (en) 2000-01-26 2000-03-15 Astrazeneca Ab Pharmaceutical compositions
US20060063738A1 (en) * 2000-02-28 2006-03-23 Sky High, Llc Compositions containing lysophosphotidic acids which inhibit apoptosis and uses thereof
US7015199B1 (en) * 2000-06-02 2006-03-21 Neirinckx Rudi D Treatment of psoriasis through down-regulation of the EGF-receptor with topically-applied EGF
US20070087965A1 (en) * 2005-10-03 2007-04-19 Neirinckx Rudi D Treatment of psoriasis through down-regulation of the egf-receptor with topically applied egf
ATE442041T1 (de) * 2000-07-28 2009-09-15 Murphy Christopher J Medium für transplantat
HK1077740A1 (en) * 2001-12-20 2006-02-24 Ct Ingenieria Genetica Biotech Use of epidermal growth factor in the manufacture of a pharmaceutical injection composition for preventing diabetic limb amputation
EP1482966B1 (en) * 2002-03-12 2014-05-14 Bio-Click Technologies Ltd Method and composition for treating skin wounds with epidermal growth factor
SE0202719D0 (sv) * 2002-09-13 2002-09-13 Pharmacia Ab Process for mfg crystals of growth hormone
US20050214382A1 (en) * 2004-03-29 2005-09-29 Erning Xia Zinc preservative composition and method of use
US20070207209A1 (en) * 2004-08-27 2007-09-06 Murphy Christopher J Trophic factor combinations for nervous system treatment
US8481049B2 (en) 2005-05-27 2013-07-09 Bharat Biotech International Limited Methods for treating a wound using epidermal growth factor formulation
CU23411B6 (es) * 2005-12-29 2009-09-08 Ct Ingenieria Genetica Biotech Uso tópico del factor de crecimiento epidérmico en liposomas para prevenir la amputación del pie diabético
CU23388B6 (es) * 2006-01-31 2009-07-16 Ct Ingenieria Genetica Biotech Composición farmacéutica de microesferas para prevenir la amputación del pie diabético
TWI394564B (zh) * 2006-09-21 2013-05-01 Alcon Res Ltd 自行保存型水性藥學組成物
EP2066300B2 (en) * 2006-09-28 2019-01-23 Novartis Ag Self-preserved aqueous pharmaceutical compositions
CU23526B6 (es) * 2006-10-03 2010-05-19 Ct Ingenieria Genetica Biotech Método para la restauración morfofuncional de nervios periféricos en la neuropatía diabética
KR100784134B1 (ko) * 2006-10-09 2007-12-12 주식회사 대웅 상피세포성장인자를 함유하는 안정한 구내염 치료용 액상조성물
US20090232763A1 (en) * 2008-03-17 2009-09-17 Kabra Bhagwati P Aqueous pharmaceutical compositions containing borate-polyol complexes
JP5303322B2 (ja) * 2009-03-13 2013-10-02 ピアス株式会社 皮膚外用組成物
TWI489997B (zh) * 2009-06-19 2015-07-01 Alcon Res Ltd 含有硼酸－多元醇錯合物之水性藥學組成物
BR112012016575A2 (pt) * 2010-01-06 2016-04-12 Orf Liftaekni Hf composição para cuidado da pele/dermatológica, fator de crescimento heterólogo produzido por planta, e, método para fabricar um produto tópico
RS59978B1 (sr) 2010-08-11 2020-03-31 Ironwood Pharmaceuticals Inc Stabilne formulacije linaklotida
JP5798356B2 (ja) * 2011-04-06 2015-10-21 一般財団法人化学及血清療法研究所 新規インフルエンザワクチン安定化剤
TR201809571T4 (tr) 2013-03-15 2018-07-23 Hoffmann La Roche Ll-22 polipeptidleri ile ıl-22 fc füzyon proteinleri ve kullanım yöntemleri.
US9283172B2 (en) 2013-12-13 2016-03-15 Growgene Biotech Inc. Use of stem cell conditioned medium to induce ZO-1 proteins expression for skin regeneration, repair and firming
KR101868966B1 (ko) * 2016-05-12 2018-06-19 주식회사 엔씨엘바이오 열 안정성을 증진시킨 사람 상피세포 성장인자의 조성물
KR20200125590A (ko) 2018-01-26 2020-11-04 제넨테크, 인크. 조성물 및 사용 방법
MA51676A (fr) 2018-01-26 2021-05-05 Hoffmann La Roche Protéines de fusion il-22 fc et procédés d'utilisation
MA51907A (fr) 2018-02-21 2021-05-26 Hoffmann La Roche Posologie pour un traitement avec des protéines de fusion il-22 fc

Family Cites Families (11)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
AU3784072A (en) * 1971-01-20 1973-07-19 Richter Gedeon Vegyeszet A process for the preparation of new complexes of biologically active peptides, polypetrides, proteins or derivatives or salts thereof having prolonged and/or increased activity
US3887704A (en) * 1974-03-12 1975-06-03 Joseph Lichtenstein Aqueous zinc solutions for physiological use
FI78616C (fi) * 1982-02-05 1989-09-11 Novo Industri As Foerfarande foer framstaellning av en foer infusionsaendamaol avsedd stabiliserad insulinloesning, som har en foerhoejd zinkhalt.
DK113585D0 (da) * 1985-03-12 1985-03-12 Novo Industri As Nye peptider
HU194280B (en) * 1985-10-22 1988-01-28 Richter Gedeon Vegyeszet Process for producing new gonadoliberin analogues of high effectivity and pharmaceutical compositions containing them
US4816568A (en) * 1986-05-16 1989-03-28 International Minerals & Chemical Corp. Stabilization of growth hormones
JPH01501389A (ja) * 1986-10-20 1989-05-18 ノボ　インダストリ　アクティーゼルスカブ ポリペプチド製剤
US4717717A (en) * 1986-11-05 1988-01-05 Ethicon, Inc. Stabilized compositions containing epidermal growth factor
US4764592A (en) * 1987-04-23 1988-08-16 Eli Lilly And Company Crystalline human proinsulin and process for its production
DE3731255A1 (de) * 1987-09-17 1989-04-06 Boehringer Ingelheim Int Stabilisierung von therapeutisch wirksamen proteinen in pharmazeutischen zubereitungen
US5272063A (en) * 1988-11-22 1993-12-21 Syntex (U.S.A.) Inc. Process of making human nerve growth factor

Also Published As

Publication number Publication date
GR1000392B (el) 1992-06-30
EP0398619A3 (en) 1991-04-03
CA2016659C (en) 1996-12-10
JPH0334992A (ja) 1991-02-14
GR900100334A (en) 1991-10-10
EP0398619A2 (en) 1990-11-22
JP2763815B2 (ja) 1998-06-11
PT94037A (pt) 1991-01-08
DE69002795D1 (de) 1993-09-23
AU630952B2 (en) 1992-11-12
EP0398619B1 (en) 1993-08-18
US5130298A (en) 1992-07-14
DK0398619T3 (da) 1993-10-04
DE69002795T2 (de) 1994-01-13
AU5496890A (en) 1990-11-22
PT94037B (pt) 1996-11-29
CA2016659A1 (en) 1990-11-16
ES2058799T3 (es) 1994-11-01

Similar Documents

Publication Publication Date Title
KR900017580A (ko) 표피 성장 인자를 함유하는 안정화된 조성물
DE3770657D1 (de) Fungizide verwendung eines cyanopyrrol-derivates.
UA41937C2 (uk) Стабільна місцеводіюча ретиноідна композиція
JPS6440433A (en) Aqueous liquid composition of thrombin
CA2366996A1 (en) Ascorbic acid composition and method for treatment of aging or damaged skin
EP0375388A3 (en) Cosmetic composition
JPS6438009A (en) Beautifying cosmetic
KR920701249A (ko) 글리코실화 인슐린
ES2108129T3 (es) Nuevos derivados de pirazina, su preparacion y empleo.
DK0615435T3 (da) Hudplejepræparat
AU629445B2 (en) Improvements in or relating to topical compositions containing 1 alpha 25-dihydroxycholecalciferol
ES8704330A1 (es) Procedimiento de preparar y almacenar composiciones comestibles edulcoradas
KR920018076A (ko) 신규 폴리펩티드
JPS6416799A (en) H-pth (1-34) composition and its preparation
BR8900337A (pt) Compostos ativo contra pragas,composicao para controle de pragas,processo para combater pragas,e processo para preparar os referidos compostos
IL43623A (en) Drug composition comprising crystallized insulin and amorphous desphenylalanine b1 insulin having antidiabetic activity
IE782515L (en) Treating diarrhoea
EP0398669A3 (en) Cosmetic composition
DE602004009128D1 (de) Kosmetische Verwendung von neuen abschuppenden Mitteln
EP0195114B1 (en) Stabilized injection compositions and their preparations
KR860000073A (ko) 기계적 응력에 대해 안정화된 수성인슐린 제제의 제조방법
IE40985B1 (en) Insulin preparations having antidiabetic activity and process for their manufacture
IE37935L (en) Sulphur compounds with cooling effect
KR890011901A (ko) 동물 성장 촉진제
KR970032513A (ko) 알로에 식초 및 이를 함유하는 음료 조성물

Legal Events

Date Code Title Description
WITN Application deemed withdrawn, e.g. because no request for examination was filed or no examination fee was paid